Abstract Book - PDF - San Antonio Breast Cancer Symposium

More documents

Recommendations

Info

CTRC-AACR San Antonio Breast Cancer Symposium OT1-1-03 OT1-1-04 PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer Earl HM, Cameron DA, Miles D, Wardley AM, Ogburn ERM, Vallier A-L, Loi S, Higgins HB, Hiller L, Dunn JA. University of Cambridge, Cambridge, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom; Edinburgh University, Edinburgh, United Kingdom; Mount Vernon Cancer Centre, Middlesex, United Kingdom; The Christie Hospital, Manchester, United Kingdom; Warwick Clinical Trials Unit, University of Warwick, Coventry, United Kingdom; Cambridge Cancer Trials Centre, Cambridge. ALTERNATIVE: safety and efficacy of lapatinib (L), trastuzumab (T), or both in combination with an aromatase inhibitor (AI) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer Johnston S, Wroblewski S, Huang Y, Harvey C, Nagi F, Franklin N, Gradishar W. Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Stockley Park, United Kingdom; Northwestern University, Chicago, IL. A Phase I pharmacokinetics trial comparing PF-05280014 and trastuzumab in healthy volunteers (REFLECTIONS B327-01) Ricart AD, Zacharchuk C, Reich SD, Meng X, Barker KB, Taylor CT, Hansson AG. Pfizer Inc., San Diego, CA; Pfizer Inc., Cambridge, MA; Pfizer Inc., New Haven, CT. A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer Crown JP, Moulton B, O’Donovan N. St Vincent’s University Hospital, Elm Park, Dublin, Ireland; ICORG (All Ireland Cooperative Oncology Research Group), Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland. Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515) Lin N, Danso MA, David AK, Muscato J, Rayson D, Houck, III WA, Ellis C, DeSilvio M, Garofalo A, Nagarwala Y, Winer E. Dana-Farber Cancer Institute, Boston, MA; Virginia Oncology Associates, Norfolk, VA; Augusta Oncology Associates, Augusta, GA; Missouri Cancer Associates, Columbia, MO; QEII Health Sciences Centre, Halifax, NS, Canada; Virginia Cancer Specialists, PC, Winchester, VA; GlaxoSmithKline Oncology, Collegeville, PA. Clinical outcomes among ErbB2+ MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study) Abulkhair O, Uslu R, Sezgin C, Büyükberber S, Darwish T, Isikdogan A, Gumus M, Dane F, Sevinc A, Halawani H, Uncu D, Marrero N, Tobler J, Soares C, Landis S, Moraes E, Gidekel R, Santillana S, Nunez P, Cagnolati S, Rodriguez JG. Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hospital, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina. OT1-1-09 OT1-1-10 Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER2-positive breast cancer Gavilá J, Llombart A, Guerrero A, Ruiz A, Guillem V. Fundación Instituto Valenciano de Oncología, Valencia, Spain; Hospital Arnau de Vilanova, Valencia, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain. DETECT III - A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells Melcher CA, Janni JW, Schneeweiss A, Fasching PA, Hagenbeck CD, Aktas B, Pantel K, Solomayer EF, Ortmann U, Jaeger BAS, Mueller V, Rack BK, Fehm TN. University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany. TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases Freedman RA, Gelman RS, Wefel JS, Krop IE, Melisko ME, Ly A, Agar NYR, Connolly RM, Blackwell KL, Nabell LM, Ingle JN, Van Poznak CH, Puhalla SL, Niravath PA, Ryabin N, Wolff AC, Winer EP, Lin N. Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; University of California, San Francisco, CA; Brigham and Women’s Hospital, Boston, MA; Johns Hopkins University, Baltimore, MD; Duke University, Durham, NC; University of Alabama, Birmingham, AL; Mayo Clinic, Rochester, MN; University of Michigan, Ann Arbor, MI; Univerity of Pittsburgh, Pittsburgh, PA; Baylor, Houston, TX, NSABP FB-7 Trial: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer Lu J, Jacobs SA, Buyse ME, Paik S, Wolmark N. State University of New York at Stony Brook, Stony Brook, NY; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA. Dual blockade with Afatinib and Trastuzumab as neoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70 Hanusch C, Schneeweiss A, Untch M, Paepke S, Kuemmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Loibl S, Nekljudova V, von Minckwitz G. Rotkreuzklinikum Muenchen; University Heidelberg; Helios Klinik Berlin; Frauenklinik Muenchen; Kliniken Essen Mitte; Klinikum offenbach; University Duesseldorf; Eilenriedeklinik Düsseldorf; University Rostock; University Kiel; Charite Berlin; University Magdeburg; Sankt Gertrauden Berlin; German Breast Group, Neu- Isenburg. Open-label, Phase II trial of afatinib, with or without vinorelbine, for the treatment of HER2-overexpressing inflammatory breast cancer (IBC)* Swanton C, Cromer J, On behalf of the 1200.89 trial group. CR-UK London Research Institute, London, United Kingdom; Boehringer Ingelheim, North Ryde, Australia. OT1-1-05 OT1-1-06 OT1-1-07 OT1-1-08 OT1-1-11 OT1-1-12 OT1-1-13 OT1-1-14 Cancer Res; 72(24 Suppl.) December 15, 2012 18s Cancer Research
December 4–8, 2012 Program Schedule OT1-1-15 LUX-Breast 3: Randomized Phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator’s choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/ or lapatinib-based therapy* Joensuu H, Ould-Kaci M, On behalf of the 1200.67 trial group. Helsinki University Central Hospital, Helsinki, Finland; Boehringer Ingelheim, Paris, France. OT1-1-16 LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment* Xu B, Im S-A, Huang C-S, Im Y-H, Ro J, Zhang Q, Arora R, Mehta A, Jung K, Yeh D-C, Lee S, Jassem J, Wojtukiewicz M, Chen S-C, Lahogue A, Uttenreuther-Fischer M, Hurvitz S-A, Harbeck N, Piccart- Gebhart M, On behalf of the LUX-Breast 1 study group. Chinese Academy of Medical Sciences, Beijing, China; Seoul National University Hospital, Seoul, Korea; National Taiwan University Hospital, Taipei, Taiwan; Samsung Medical Center, Seoul, Korea; National Cancer Center, Goyang, Korea; Third Affiliated Hospital of Harbin Medical University, Heilongjiang Province, China; Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, Amravati, India; Central India Cancer Research Institute, Nagpur, India; Asan Medical Center, Seoul, Korea; Taichung Veterans General Hospital, Taichung, Taiwan; Severance Hospital, Seoul, Korea; Medical University, Gdansk, Poland; Medical University, Bialystok, Poland; Chang Gung Memorial Hospital - Linkou Branch, Taoyuan County, Taiwan; SCS Boehringer- Ingelheim Comm.V, Brussels, Belgium; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; UCLA, Los Angeles, CA; University of Munich, Munich, Germany; Institut Jules Bordet, Brussels, Belgium. OT1-1-17 LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib* Hickish T, Mehta A, Jain M, Huang C-S, Kovalenko N, Udovitsa D, Pemberton K, Uttenreuther-Fischer M, Tseng L-M, On behalf of the LUX-Breast 2 study group. Bournemouth Hospital, Bournemouth University, Dorset, United Kingdom; Central India Cancer Research Institute, Maharashtra, India; Ruby Hall Clinic, Maharashtra, India; National Taiwan University Hospital, Taipei, Taiwan; Regional Clinical Oncology Dispensary, Stavropol, Russian Federation; GUZ Oncological Dispesary #2, Sochi, Russian Federation; Boehringer Ingelheim Limited, Bracknell, United Kingdom; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Taipei Veterans General Hospital, National Yang Ming University, Taipei, Taiwan. Ongoing Trials 1: Radiation Therapy OT1-2-01 NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx) Cobleigh MA, Anderson SJ, Julian TB, Siziopikou KP, Arthur DW, Rabinovitch R, Zheng P, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Rush University Medical Center, Chicago, IL; University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA; Northwestern University Feinberg School of Medicine, Chicago, IL; Virginia Commonwealth University, Richmond, VA; University of Colorado, Aurora, CO; Aultman Hospital, Canton, OH. OT1-2-02 SHARE. A French multicenter phase III trial comparing accelerated partial irradiation (APBI) versus standard or hypofractionated whole breast irradiation in low risk of local recurrence breast cancer Belkacemi Y, Bourgier C, Kramar A, Lemonier J, Auzac G, Dumas I, Lacornerie T, Mijonnet S, Mege J-P, Lartigau E. APHP; GH Henry Mondor and UPEC, Paris, Créteil, France; Institut Gustave Roussy, Villejuif, France; Oscar Lambret Center, Lille, France; UNICANCER, Paris, France. 7:30 pm–9:30 pm OPEN SATELLITE EVENT presented by Research to Practice Marriott Rivercenter ONE YEAR LATER: The Practical Application of Research Advances in the Management of Early and Advanced Breast cancer Website: http://www.researchtopractice.com/Meetings/SA2012 Thursday, December 6, 2012 6:45 am–5:15 pm Registration Bridge Hall 7:00 am–9:00 am Poster Discussion 3: Metformin/Statins Ballroom A Viewing 7:00 am Discussion 7:45 am Adrian Lee, PhD, Chair University of Pittsburgh Cancer Institute Pittsburgh, PA Michael Pollak, MD, Discussant McGill University Montreal, CANADA and Vered Stearns, MD, Discussant The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD PD03-01 Effect of metformin on apoptosis in a presurgical trial in nondiabetic patients with breast cancer Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Guerrieri-Gonzaga A, Dell’Orto P, Gentilini OD, Vingiani A, Pagani G, Puccio A, Bonanni B. European Institute of Oncology (EIO), Milan; Ospaedali Galliera, Genova; University of Milan. PD03-02 Evidence for the anti-cancer action of metformin mediated via tumor AMPK, Akt and Ki67, in a preoperative window of opportunity trial Hadad SM, Dowling RJO, Chang MC, Done SJ, Purdie CA, Jordan LB, Dewar J, Goodwin PJ, Stambolic V, Thompson AM. University of Sheffield, United Kingdom; University Health Network, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; University of Dundee, United Kingdom; Princess Margaret Hospital and Mount Sinai Hospital, Toronto, Canada. PD03-03 Pre-surgical trial of metformin in overweight and obese, multiethnic patients with newly diagnosed breast cancer Kalinsky K, Crew KD, Refice S, Wang A, Feldman SM, Taback B, Hibshoosh H, Maurer M, Hershman DL. Columbia University Medical Center, New York, NY. PD03-04 Discovery of metformin derivatives with potent antitumor activity in triple-negative breast cancer Márquez-Garbán DC, Deng G, Anderson N, Aivazyan L, Kazmi N, Hamilton N, Jung ME, Pietras RJ. UCLA, Los Angeles, CA. PD03-05 Analysis of tumour cell signaling in response to neoadjuvant metformin in women with early stage breast cancer Dowling RJO, Niraula S, Chang MC, Done SJ, Ennis M, Hood N, McCready DR, Leong W, Escallon JM, Reedijk M, Goodwin PJ, Stambolic V. Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada. www.aacrjournals.org 19s Cancer Res; 72(24 Suppl.) December 15, 2012
Page 1 and 2: Cancer Research December 15, 2012
Page 3 and 4: Editor-in-Chief George C. Prenderga
Page 5 and 6: December 4-8, 2012 Program Schedule
Page 19 and 20: CTRC-AACR San Antonio Breast Cancer
Page 21: December 4-8, 2012 Program Schedule
Page 73 and 74:
December 4-8, 2012 Program Schedule
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
December 4-8, 2012 Abstracts: Invit
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
December 4-8, 2012 Abstracts: Gener
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
December 4-8, 2012 Abstracts: Poste
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329 and 330:
Page 331 and 332:
Page 333 and 334:
Page 335 and 336:
Page 337 and 338:
Page 339 and 340:
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Page 359 and 360:
Page 361 and 362:
Page 363 and 364:
Page 365 and 366:
Page 367 and 368:
Page 369 and 370:
Page 371 and 372:
Page 373 and 374:
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
Page 403 and 404:
Page 405 and 406:
Page 407 and 408:
Page 409 and 410:
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
Page 421 and 422:
Page 423 and 424:
Page 425 and 426:
Page 427 and 428:
Page 429 and 430:
Page 431 and 432:
Page 433 and 434:
Page 435 and 436:
Page 437 and 438:
Page 439 and 440:
Page 441 and 442:
Page 443 and 444:
Page 445 and 446:
Page 447 and 448:
Page 449 and 450:
Page 451 and 452:
Page 453 and 454:
Page 455 and 456:
Page 457 and 458:
Page 459 and 460:
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
Page 481 and 482:
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489 and 490:
Page 491 and 492:
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
Page 499 and 500:
Page 501 and 502:
Page 503 and 504:
Page 505 and 506:
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
Page 513 and 514:
Page 515 and 516:
Page 517 and 518:
Page 519 and 520:
Page 521 and 522:
Page 523 and 524:
Page 525 and 526:
Page 527 and 528:
Page 529 and 530:
Page 531 and 532:
Page 533 and 534:
Page 535 and 536:
Page 537 and 538:
Page 539 and 540:
Page 541 and 542:
Page 543 and 544:
Page 545 and 546:
Page 547 and 548:
Page 549 and 550:
Page 551 and 552:
Page 553 and 554:
Page 555 and 556:
Page 557 and 558:
Page 559 and 560:
Page 561 and 562:
Page 563 and 564:
Page 565 and 566:
Page 567 and 568:
Page 569 and 570:
Page 571 and 572:
Page 573 and 574:
Page 575 and 576:
Page 577 and 578:
Page 579 and 580:
Page 581 and 582:
Page 583 and 584:
Page 585 and 586:
Page 587 and 588:
Page 589 and 590:
Page 591 and 592:
December 4-8, 2012 Author Index 120
Page 593 and 594:
December 4-8, 2012 Author Index Bon
Page 595 and 596:
December 4-8, 2012 Author Index Cui
Page 597 and 598:
December 4-8, 2012 Author Index Fre
Page 599 and 600:
December 4-8, 2012 Author Index Hir
Page 601 and 602:
December 4-8, 2012 Author Index Kle
Page 603 and 604:
December 4-8, 2012 Author Index Mal
Page 605 and 606:
December 4-8, 2012 Author Index Ohu
Page 607 and 608:
December 4-8, 2012 Author Index Rog
Page 609 and 610:
December 4-8, 2012 Author Index Sta
Page 611 and 612:
December 4-8, 2012 Author Index von
show all

Abstract Book - PDF - San Antonio Breast Cancer Symposium

Create successful ePaper yourself

Delete template?

Save as template?